Bio Essence Corporation
BIOE
$0.206
-$0.008-3.74%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 171.96% | -13.49% | -83.94% | -- | -24.30% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 171.96% | -13.49% | -83.94% | -- | -24.30% |
| Cost of Revenue | -- | -60.37% | -91.66% | -- | -- |
| Gross Profit | -- | 300.99% | -73.38% | -- | -- |
| SG&A Expenses | 126.93% | -38.11% | -42.27% | 524.69% | -669.62% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 121.52% | -44.09% | -47.36% | 524.69% | -191.91% |
| Operating Income | -98.46% | 57.82% | 5.47% | -524.69% | 295.92% |
| Income Before Tax | -112.77% | -281.04% | 23.60% | -432.47% | 218.41% |
| Income Tax Expenses | 100.00% | -- | -75.00% | -- | -128.57% |
| Earnings from Continuing Operations | -112.67% | -281.04% | 24.18% | -432.47% | 217.49% |
| Earnings from Discontinued Operations | 100.00% | -- | -- | 264.89% | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 85.75% | -281.04% | 24.18% | 174.89% | 9.15% |
| EBIT | -98.46% | 57.82% | 5.47% | -524.69% | 295.92% |
| EBITDA | -98.16% | 55.74% | -1.66% | -594.04% | 447.54% |
| EPS Basic | 89.23% | -280.72% | 30.49% | 164.81% | -1.56% |
| Normalized Basic EPS | -120.00% | 42.86% | 31.37% | -400.00% | 92.31% |
| EPS Diluted | 89.23% | -280.72% | 30.49% | 164.81% | -1.56% |
| Normalized Diluted EPS | -120.00% | 42.86% | 31.37% | -400.00% | 92.31% |
| Average Basic Shares Outstanding | 11.94% | 0.00% | 9.50% | 15.15% | 2.86% |
| Average Diluted Shares Outstanding | 11.94% | 0.00% | 9.50% | 15.15% | 2.86% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |